Suppr超能文献

非甾体选择性雄激素受体调节剂S-3-(4-乙酰氨基苯氧基)-2-羟基-2-甲基-N-(4-硝基-3-三氟甲基苯基)丙酰胺在大鼠体内的药代动力学

Pharmacokinetics of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro- 3-trifluoromethyl-phenyl)-propionamide in rats, a non-steroidal selective androgen receptor modulator.

作者信息

Kearbey J D, Wu D, Gao W, Miller D D, Dalton J T

机构信息

Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.

出版信息

Xenobiotica. 2004 Mar;34(3):273-80. doi: 10.1080/0049825041008962.

Abstract

1: S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide (also known as S-4) is a non-steroidal selective androgen receptor modulator demonstrating tissue-selective androgenic and anabolic effects. The purpose of the present study was to examine the systemic pharmacokinetics, elimination and oral bioavailability of S-4 in rats. 2: Thirty-five male Sprague-Dawley rats weighing approximately 250 g were randomly assigned to one of seven treatment groups. Intravenous doses of 0.5, 1, 10, and 30 mg kg(-1) were given via a jugular catheter. Oral doses of 1, 10 and 30 mg kg(-1) were administered via gavage. Plasma concentrations were determined using a validated high-performance liquid chromatography or by a high-performance liquid chromatography/mass spectrometry method. 3: Clearances ranged between 1.0 and 2.1 ml min(-1) kg(-1) and varied with dose. The volume of distribution was approximately 0.448 l kg(-1) in all treatment groups. Oral bioavailability was also dose dependent, with the lower doses showing complete oral bioavailability. The half-life of S-4 over the dose range tested was between 2.6 and 5.3 h. 4: It was demonstrated that S-4 is rapidly absorbed, slowly cleared, and has a moderate volume of distribution in rats. The pharmacokinetics and oral bioavailability of S-4 indicate that it is an excellent candidate for clinical development.

摘要

1: S-3-(4-乙酰氨基-苯氧基)-2-羟基-2-甲基-N-(4-硝基-3-三氟甲基-苯基)-丙酰胺(也称为S-4)是一种非甾体选择性雄激素受体调节剂,具有组织选择性雄激素和合成代谢作用。本研究的目的是考察S-4在大鼠体内的全身药代动力学、消除情况及口服生物利用度。2: 35只体重约250 g的雄性Sprague-Dawley大鼠被随机分配到七个治疗组之一。通过颈静脉导管给予静脉注射剂量0.5、1、10和30 mg·kg⁻¹。通过灌胃给予口服剂量1、10和30 mg·kg⁻¹。使用经过验证的高效液相色谱法或高效液相色谱/质谱法测定血浆浓度。3: 清除率在1.0至2.1 ml·min⁻¹·kg⁻¹之间,随剂量变化。所有治疗组的分布容积约为0.448 l·kg⁻¹。口服生物利用度也呈剂量依赖性,较低剂量显示完全口服生物利用度。在所测试的剂量范围内,S-4的半衰期在2.6至5.3小时之间。4: 结果表明,S-4在大鼠体内吸收迅速、清除缓慢且分布容积适中。S-4的药代动力学和口服生物利用度表明它是临床开发的优秀候选药物。

相似文献

2
In vivo metabolism and final disposition of a novel nonsteroidal androgen in rats and dogs.
Drug Metab Dispos. 2006 Oct;34(10):1713-21. doi: 10.1124/dmd.106.009985. Epub 2006 Jun 30.
6
A selective androgen receptor modulator for hormonal male contraception.
J Pharmacol Exp Ther. 2005 Feb;312(2):546-53. doi: 10.1124/jpet.104.075424. Epub 2004 Sep 3.
9
Effects of selective androgen receptor modulator (SARM) treatment in osteopenic female rats.
Pharm Res. 2009 Nov;26(11):2471-7. doi: 10.1007/s11095-009-9962-7. Epub 2009 Sep 1.
10
Nonsteroidal selective androgen receptor modulators enhance female sexual motivation.
J Pharmacol Exp Ther. 2010 Aug;334(2):439-48. doi: 10.1124/jpet.110.168880. Epub 2010 May 5.

引用本文的文献

1
Nuclear receptors and their selective pharmacologic modulators.
Pharmacol Rev. 2013 Mar 1;65(2):710-78. doi: 10.1124/pr.112.006833. Print 2013 Apr.
3
Effects of selective androgen receptor modulator (SARM) treatment in osteopenic female rats.
Pharm Res. 2009 Nov;26(11):2471-7. doi: 10.1007/s11095-009-9962-7. Epub 2009 Sep 1.
4
Selective androgen receptor modulators in preclinical and clinical development.
Nucl Recept Signal. 2008;6:e010. doi: 10.1621/nrs.06010. Epub 2008 Nov 26.
5
Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats.
Pharm Res. 2007 Feb;24(2):328-35. doi: 10.1007/s11095-006-9152-9. Epub 2006 Oct 25.
6
Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging.
Nat Clin Pract Endocrinol Metab. 2006 Mar;2(3):146-59. doi: 10.1038/ncpendmet0120.
7
Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands.
Pharm Res. 2006 Aug;23(8):1641-58. doi: 10.1007/s11095-006-9024-3.

本文引用的文献

2
Pharmacodynamics of selective androgen receptor modulators.
J Pharmacol Exp Ther. 2003 Mar;304(3):1334-40. doi: 10.1124/jpet.102.040840.
3
Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium.
J Clin Endocrinol Metab. 1999 Oct;84(10):3459-62. doi: 10.1210/jcem.84.10.6122.
4
Testosterone replacement therapy.
Arch Androl. 1998 Sep-Oct;41(2):79-90. doi: 10.3109/01485019808987949.
5
Discovery of nonsteroidal androgens.
Biochem Biophys Res Commun. 1998 Mar 6;244(1):1-4. doi: 10.1006/bbrc.1998.8209.
6
Clinical review 85: Emerging issues in androgen replacement therapy.
J Clin Endocrinol Metab. 1997 Jan;82(1):3-8. doi: 10.1210/jcem.82.1.3640.
7
Physiological parameters in laboratory animals and humans.
Pharm Res. 1993 Jul;10(7):1093-5. doi: 10.1023/a:1018943613122.
8
Metabolism of Casodex in laboratory animals.
Xenobiotica. 1993 Jul;23(7):781-98. doi: 10.3109/00498259309166784.
9
The pathogenesis of gynecomastia.
Adv Intern Med. 1980;25:1-32.
10
Hepatotoxic effects of the anabolic/androgenic steroids.
Semin Liver Dis. 1987 Aug;7(3):230-6. doi: 10.1055/s-2008-1040579.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验